Spirair Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
24
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$24.7M
- Investors
-
6
Spirair General Information
Description
Developer of minimally invasive medical devices designed to treat nasal septal deviation. The company's device transforms the nasal obstruction treatment procedure from surgery to an in-office procedure, providing doctors with strong outcomes and a better patient experience.
Contact Information
Website
www.spirair.comCorporate Office
- 415 Grand Avenue
- Suite 201
- South San Francisco, CA 94080
- United States
Corporate Office
- 415 Grand Avenue
- Suite 201
- South San Francisco, CA 94080
- United States
Spirair Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC (Series B) | 10-Mar-2026 | $24.7M | Completed | Generating Revenue | ||
| 1. Early Stage VC (Series A) | 18-Aug-2021 | Completed | Generating Revenue |
Spirair Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A-2 | 1,887,264 | $0.000010 | $1.1 | $1.1 | 1x | $1.1 | 4.12% | |
| Series A-1 | 6,290,343 | $0.000010 | $1.41 | $1.41 | 1x | $1.41 | 13.75% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Spirair Patents
Spirair Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260137406-A1 | Minimally invasive nasal turbinate surgery | Pending | 18-Nov-2024 | ||
| WO-2026107520-A1 | Minimally invasive nasal turbinate surgery | Pending | 18-Nov-2024 | ||
| US-20260137477-A1 | Minimally invasive shaping of nasal tissues | Pending | 18-Nov-2024 | ||
| WO-2026107517-A1 | Minimally invasive shaping of nasal tissues | Pending | 18-Nov-2024 | ||
| AU-2023391051-A1 | Devices, systems, and methods for manipulating nasal tissues | Pending | 09-Dec-2022 | A61F5/08 |
Spirair Signals
Spirair Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 1809 Capital | Venture Capital | Minority | ||
| Cadence Healthcare Ventures | Venture Capital | Minority | ||
| Led By Reason | Venture Capital | Minority | ||
| MedVenture Partners (Japan) | Venture Capital | Minority | ||
| Sonder Capital Management | Venture Capital | Minority |
Spirair FAQs
-
When was Spirair founded?
Spirair was founded in 2020.
-
Where is Spirair headquartered?
Spirair is headquartered in South San Francisco, CA.
-
What is the size of Spirair?
Spirair has 24 total employees.
-
What industry is Spirair in?
Spirair’s primary industry is Surgical Devices.
-
Is Spirair a private or public company?
Spirair is a Private company.
-
What is the current valuation of Spirair?
The current valuation of Spirair is .
-
What is Spirair’s current revenue?
The current revenue for Spirair is .
-
How much funding has Spirair raised over time?
Spirair has raised $34.7M.
-
Who are Spirair’s investors?
1809 Capital, Cadence Healthcare Ventures, Led By Reason, MedVenture Partners (Japan), and Sonder Capital Management are 5 of 6 investors who have invested in Spirair.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process